Latest Hematologic disease Stories
To mark National Sickle Cell Month which occurs every September, the Editorial Board of Living with a Disability magazine has published an important new article that sheds light on hematological
PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc.
In response to blood cancer re-classifications by the World Health Organization, the MPD Foundation announces it is changing its name to Myeloproliferative Neoplasms (MPN) Research Foundation. Chicago, IL (PRWEB) April 4, 2011 The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known as...
SAN DIEGO, Dec. 3, 2010 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin-associated diseases, announced the addition of three experienced executives to the management team. John P.
PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc.
CHESHIRE, Conn., Nov. 10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the American Society of Hematology (ASH) has published additional data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH).
HemaQuest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally administered therapeutic under clinical development for these two indications.